

Indikation	Neo-Adjuvant	Adjuvant	Preventiv	Paliativ	Linie	Kurztitel	Vollständiger Titel	ER+ HER2-	ER+ HER+	ER- HER2+	TNBC
							AMG-Studien				
Mamma-Ca		x				SASCIA EudraCT Number 2019-004100-35	Phase III postneoadjuvant study evaluating Sacituzumab Govitecan , an Antibody Drug Conjugate in primary HER2- negative breast cancer patients with high relapse risk after standard neoadjuvant treatment - SASCIA	x			x
Mamma-Ca				x		SERENA-6 EudraCT Number 2021-000546-17	A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor (Palbociclib or Abemaciclib) vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor A ctDNA Guided Early Switch Study	x			
Mamma-Ca		x				DESTINY-Breast05 GBG103 EudraCT Number	A phase 3, multicenter, randomized, open-label, active-controlled study of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in subjects with high-risk HER2-positive primary breast cancer who have residual invasive disease in breast or axillary lymph nodes following neoadjuvant therapy (DESTINY-Breast05)		x	x	
Mamma-Ca				x		ASCENT-3 GS-US-592-6238 EudraCT Number 2021-005742-14	A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1				x
Mamma-Ca				x		ASCENT-4 GS-US-592-6173 EudraCT Number 2021-005743-79	A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1				x
Mamma-Ca		x				CAMBRIA-1 EudraCT Number 2022-501024-20-00	A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degradar) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence	x			



Indikation	Neo-Adjuvant	Adjuvant	Preventiv	Paliativ	Linie	Kurtztitel	Vollständiger Titel	ER+ HER2-	ER+ HER+	ER- HER2+	TNBC
Mamma-Ca						Reko Hammor	Prospektive Kohortenstudie zur Erfassung der Lebensqualität, des chirurgischen Outcomes und perioperativer Komplikationen nach implantatbasierter Brustrekonstruktion				
		Primär		Metastasiert							
Ovar-Ca				x		FraStrROC	Development and prospective validation of a Frailty Score for chemotherapy associated side effects in Relapsed Ovarian Cancer				
Ovar-Ca				x		MIROVA AGO-OVAR 2.34 EudraCT Number 2018-004207-39	A randomized phase II trial of Mirvetuximab soravtansine (IMGN853) , in folate receptor alpha (FR α) high recurrent ovarian cancer eligible for platinum-based chemotherapy. (Protocol ID: AGO-OVAR 2.34).				
Ovar-Ca		x				AGO-OVAR 28 / ENGOT-ov57 EudraCT Number 2021-001271-16	Niraparib vs Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial) (Protocol-code: AGO-OVAR 28 / ENGOT-ov57)				

Sonstige Studien											
Mamma- Ca und Schwangerschaft						GBG 29 BCP	Prospektive Registerstudie zur Diagnostik und Therapie des Mamma-karzinoms in der Schwangerschaft Pat. mit histologisch gesichertem Mammakarzinom und Schwangerschaft	x	x	x	x
Mamma-Ca				x		GBG79 BrainMet	Brain Metastases in Breast Cancer Network Germany (BMBC) Meeting a clinical need for the improvement of patient outcome	x	x	x	x
Mamma-Ca beim Mann						Register Magdeburg	Mammakarzinom des Mannes. Eine prospektive Registerstudie der Universitätsfrauenklinik Magdeburg in Zusammenarbeit mit den klinischen Krebsregistern zur Diagnostik und Therapie des Mammakarzinoms des Mannes	x	x	x	x



Indikation	Neo-Adjuvant	Adjuvant	Preventiv	Paliativ	Linie	Kurztitel	Vollständiger Titel	ER+ HER2-	ER+ HER+	ER- HER2+	TNBC
alle gyn. Tumorpatienten						Psychonkologische Studie von ONKOTRAKT	Epidemiologische Untersuchung zur Belastung von Krebspatienten (Verbesserung der Erkennung des psychoonkologischen Betreuungsbedarfs bei Krebskranken)				
Gyn-Sarkome						REGSA	Deutsche prospektive Registerstudie zur Erfassung der Behandlung von gynäkologischen Sarkomen in der				